Bin-Chao Wang

1.4k total citations
21 papers, 560 citations indexed

About

Bin-Chao Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Bin-Chao Wang has authored 21 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Bin-Chao Wang's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Lung Cancer Research Studies (6 papers). Bin-Chao Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Lung Cancer Research Studies (6 papers). Bin-Chao Wang collaborates with scholars based in China, Australia and Hong Kong. Bin-Chao Wang's co-authors include Yi‐Long Wu, Qing Zhou, Hua‐Jun Chen, Hong‐Hong Yan, Xu‐Chao Zhang, Chong‐Rui Xu, Jin‐Ji Yang, Jian Su, Wen‐Zhao Zhong and Yi-Sheng Huang and has published in prestigious journals such as Journal of Clinical Oncology, Frontiers in Immunology and European Journal of Cancer.

In The Last Decade

Bin-Chao Wang

20 papers receiving 550 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bin-Chao Wang China	9	426	386	172	133	40	21	560
Kaiqi Du China	14	274 0.6×	227 0.6×	100 0.6×	162 1.2×	25 0.6×	35	438
Monica Milano Italy	10	138 0.3×	311 0.8×	176 1.0×	134 1.0×	42 1.1×	22	489
Ines Figueiredo United Kingdom	11	356 0.8×	237 0.6×	232 1.3×	185 1.4×	21 0.5×	26	576
Jieling Miao United States	13	300 0.7×	353 0.9×	178 1.0×	204 1.5×	47 1.2×	27	547
Shinichi Tomisaki Japan	13	264 0.6×	209 0.5×	135 0.8×	141 1.1×	55 1.4×	20	542
Joao V. Alessi United States	14	373 0.9×	492 1.3×	214 1.2×	229 1.7×	89 2.2×	57	709
M.V. Bluthgen France	8	238 0.6×	243 0.6×	180 1.0×	98 0.7×	49 1.2×	18	424
Antonio Russo Italy	8	270 0.6×	296 0.8×	155 0.9×	114 0.9×	33 0.8×	14	428
Christie J. Lau United States	10	288 0.7×	264 0.7×	159 0.9×	148 1.1×	38 0.9×	14	503
Esther E.E. Drees Netherlands	6	110 0.3×	115 0.3×	224 1.3×	216 1.6×	90 2.3×	11	373

Countries citing papers authored by Bin-Chao Wang

Since Specialization

Citations

This map shows the geographic impact of Bin-Chao Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bin-Chao Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bin-Chao Wang more than expected).

Fields of papers citing papers by Bin-Chao Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bin-Chao Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bin-Chao Wang. The network helps show where Bin-Chao Wang may publish in the future.

Co-authorship network of co-authors of Bin-Chao Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Bin-Chao Wang. A scholar is included among the top collaborators of Bin-Chao Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bin-Chao Wang. Bin-Chao Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jänne, Pasi A., Bin-Chao Wang, Byoung Chul Cho, et al.. (2025). First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Journal of Clinical Oncology. 43(13). 1553–1563. 7 indexed citations

Liu, Si‐Yang Maggie, Jie Huang, Jia‐Yi Deng, et al.. (2023). PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial. Science Bulletin. 69(4). 535–543. 18 indexed citations

Wang, Zhen, Xu‐Chao Zhang, Weineng Feng, et al.. (2023). Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients. Therapeutic Advances in Medical Oncology. 15. 2612554–2612554. 5 indexed citations

Zhang, Jia‐Tao, Yi Pan, Xuan Gao, et al.. (2023). Prospective dynamic sampling and molecular residual disease monitoring to predict clinical outcomes for patients with unresectable, locally advanced non-small cell lung cancer undergoing radical radiotherapy.. Journal of Clinical Oncology. 41(16_suppl). 8549–8549.

Zhao, Ruocong, Shanglin Li, Jiang Lv, et al.. (2021). Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer. Frontiers in Immunology. 12. 660488–660488. 50 indexed citations

Li, Wenfeng, Jun‐Tao Lin, Hong‐Hong Yan, et al.. (2020). Predictive and Prognostic Potential of TP53 in Patients With Advanced Non–Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901). Clinical Lung Cancer. 22(2). 100–109.e3. 36 indexed citations

Xu, Chong‐Rui, Yue‐Li Sun, Yang-Si Li, et al.. (2020). Safety of nivolumab/pembrolizumab in hepatitis B surface antigen-positive non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology. 38(15_suppl). e21670–e21670. 1 indexed citations

Wang, Zhen, Cheng Huang, Jin‐Ji Yang, et al.. (2019). A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). European Journal of Cancer. 109. 183–191. 11 indexed citations

Kang, Jin‐Hyoung, Huajun Chen, Qing Zhou, et al.. (2017). Primary resistance to ALK inhibitor in ALK-positive non-small-cell lung cancer.. Journal of Clinical Oncology. 35(15_suppl). 9063–9063. 3 indexed citations

10.

Li, Wenfeng, Jin‐Hyoung Kang, Xu‐Chao Zhang, et al.. (2017). Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer.. Journal of Clinical Oncology. 35(15_suppl). e20636–e20636. 7 indexed citations

11.

Wu, Yi‐Long, Jin‐Ji Yang, Xu‐Chao Zhang, et al.. (2016). Response to tyrosine kinase inhibitors in advanced non-small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation.. Journal of Clinical Oncology. 34(15_suppl). 9054–9054. 1 indexed citations

12.

Zhang, Xu‐Chao, Hua‐Jun Chen, Qing Zhou, et al.. (2016). Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Oncotarget. 7(40). 65185–65195. 34 indexed citations

13.

Zhong, Wen‐Zhao, Wei Li, Xue‐Ning Yang, et al.. (2015). Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis.. PubMed. 7(7). 1205–12. 7 indexed citations

14.

Wang, Zhen, Hong‐Hong Yan, Jin‐Ji Yang, et al.. (2014). Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. Supportive Care in Cancer. 23(3). 635–641. 24 indexed citations

15.

Zhou, Qing, Jin‐Ji Yang, Xu‐Chao Zhang, et al.. (2014). Overall survival in patients with advanced non-small cell lung cancer harboring concomitant EGFR mutations and ALK rearrangements: A cohort study.. Journal of Clinical Oncology. 32(15_suppl). e19010–e19010. 2 indexed citations

16.

Zhang, Xu‐Chao, Jin‐Ji Yang, Hua‐Jun Chen, et al.. (2014). MET overexpression as a promising therapeutic target in non-small cell lung cancer with acquired resistance to EGFR TKIs.. Journal of Clinical Oncology. 32(15_suppl). e19047–e19047. 2 indexed citations

17.

Yang, Jin‐Ji, Qing Zhou, Ri-Qiang Liao, et al.. (2012). Nedaplatin/gemcitabine versus carboplatin/gemcitabine in treatment of advanced non-small cell lung cancer: A randomized clinical trial. Chinese Journal of Cancer Research. 24(2). 97–102. 10 indexed citations

18.

Yang, Jin‐Ji, Hua‐Jun Chen, Hong‐Hong Yan, et al.. (2012). Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer. 79(1). 33–39. 141 indexed citations

19.

Zhou, Qing, Xu‐Chao Zhang, Zhihong Chen, et al.. (2011). Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(24). 3316–3321. 199 indexed citations

20.

Wang, Bin-Chao, et al.. (2004). [The detection of Rb2/p130 and p53 gene mutations by denaturing high-performance liquid chromatography analysis of sputum of lung cancer patients and its clinical implications].. PubMed. 43(7). 499–501. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact